Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02453841 · ClinicalTrials.gov registry record · NA
Prospective Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption
A NA study of Adenoidectomy and Functional Endoscopic Sinus Surgery (FESS), sponsored by Richard Cartabuke.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02453841 is a NA study of Adenoidectomy and Functional Endoscopic Sinus Surgery (FESS) that has completed, run by Richard Cartabuke. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02453841, a NA study of Adenoidectomy and Functional Endoscopic Sinus Surgery (FESS), has completed, sponsored by Richard Cartabuke.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This proposed study will assess the hemodynamic effects and measure the systemic absorption of topically applied oxymetazoline in patients undergoing functional endoscopic sinus surgery, turbinate surgery, or adenoidectomy. These patients will be receiving oxymetazoline as standard of care during the surgery.
Conditions Studied
Interventions
- DRUG Oxymetazoline
Study Locations (1)
Ohio
- Nationwide Children's Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-04-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02453841
The ClinicalTrials.gov registry entry for NCT02453841 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Richard Cartabuke, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Adenoidectomy appearing as the primary indexed condition, and to 1 intervention - of which Oxymetazoline is the first listed.
NCT02453841 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02453841 about?
NCT02453841 is a clinical study titled "Prospective Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption". This proposed study will assess the hemodynamic effects and measure the systemic absorption of topically applied oxymetazoline in patients undergoing functional endoscopic sinus surgery, turbinate surgery, or adenoidectomy. These patients will be receiving oxymetazoline as standard of care during th...
What is the current status of trial NCT02453841?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2015-12. Estimated completion is 2017-04-20.
What conditions does trial NCT02453841 study?
This clinical trial studies the following conditions: Adenoidectomy, Functional Endoscopic Sinus Surgery (FESS), Turbinate Surgery.
What interventions are being tested in trial NCT02453841?
The interventions under investigation include: Oxymetazoline (DRUG).
Who is sponsoring clinical trial NCT02453841?
This trial is sponsored by Richard Cartabuke, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02453841 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenoidectomy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.